No open-access location is known for this record yet.
No open-access location is known for this record yet.
Clinical Guidelines5 January 2010Recommended Adult Immunization Schedule: United States, 2010*FREEAdvisory Committee on Immunization Practices†Advisory Committee on Immunization Practices†Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-1-201001050-00008 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Advisory Committee on Immunization Practices (ACIP) annually reviews the Recommended Adult Immunization Schedule (Figure) to ensure that the schedule reflects current recommendations for the licensed vaccines. In October 2009, ACIP approved the Adult Immunization Schedule for 2010, which includes several changes. A bivalent human papillomavirus vaccine (HPV2) was licensed for use in females in October 2009. The ACIP recommends vaccination of females with either HPV2 or the quadrivalent human papillomavirus vaccine (HPV4). HPV4 was licensed for use in males, and the ACIP used a permissive recommendation for use of this vaccine in males. Introductory sentences were added to the footnotes for measles, mumps, rubella, influenza, pneumococcal, hepatitis A, hepatitis B, and meningococcal vaccines. Clarifications were made to the footnotes for measles, mumps, rubella, influenza, hepatitis A, meningococcal, and Haemophilus influenzae type B (Hib) vaccines, and schedule information was added to the hepatitis B vaccine footnote.Figure. Recommended Adult Immunization Schedule: United States, 2010. Download figure Download PowerPoint Download figure Download PowerPoint This schedule has also been approved by the American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and American College of Physicians.Changes in the Schedule for 2010The 2010 schedule differs from the previous schedule as follows:The HPV footnote (footnote 2) has been revised to include language that a bivalent HPV vaccine (HPV2) has been licensed for use in females. Either HPV2 or HPV4 can be used for vaccination of females aged 19 through 26 years. In addition, language has been added to indicate that ACIP used a permissive recommendation for use of HPV4 in males.To reduce redundancy, the measles, mumps, rubella (MMR) footnote (footnote 5) has been revised by moving sentences from the measles and mumps components-specific sections, indicating that adults born before 1957 generally are immune, to the beginning of the MMR footnote. The MMR footnote has been revised to clarify which adults born during or after 1957 do not need 1 or more doses of MMR for the measles and mumps components. Interval dosing information has been added to indicate that a second dose of MMR should be administered 4 weeks after the first dose. The MMR footnote has been revised to clarify that women who do not have documentation of rubella vaccination should receive a dose of MMR. A section has been added to highlight recommendations for vaccinating health care personnel born before 1957 routinely and during outbreaks.The influenza footnote (footnote 6) has been revised to distinguish between seasonal and pandemic influenza by adding the term seasonal.The hepatitis A footnote (footnote 9) has been revised to include an indication for the hepatitis A vaccine for unvaccinated persons who anticipate close contact with an international adoptee.The hepatitis B footnote (footnote 10) has been revised to include schedule information for the 3-dose hepatitis B vaccine.The meningococcal vaccine footnote (footnote 11) has been revised to clarify that the meningococcal conjugate vaccine (MCV4) is preferred for adults aged 55 years or younger and that the meningococcal polysaccharide vaccine (MPSV4) is preferred for adults aged 56 years or older. The footnote has been revised to clarify that revaccination with MCV4 is recommended for adults previously vaccinated with MCV4 or MPSV4 and a new example of who is at increased risk is provided. Information has been added on who does not need to be revaccinated.The selected conditions for Hib footnote (footnote 12) has been revised to clarify which high-risk persons can receive 1 dose of Hib vaccine.The Adult Immunization Schedule is available in English and Spanish at www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm. General information about adult vaccination is available at www.cdc.gov/vaccines/default.htm. The ACIP statements for specific vaccines are available at www.cdc.gov/vaccine/pubs/acip-list.htm. Instructions for reporting adverse events to the Vaccine Adverse Event Reporting System are available at www.vaers.hhs.gov or by telephone (800-822-7967).Appendix: Members of the Advisory Committee on Immunization PracticesCarol J. Baker, MD (Chairman), Baylor College of Medicine, Houston, Texas; Larry K. Pickering, MD (Executive Secretary), Centers for Disease Control and Prevention, Atlanta, Georgia; Lance Chilton, MD, University of New Mexico School of Medicine, Albuquerque, New Mexico; Paul Cieslak, MD, Oregon Public Health Division, Portland, Oregon; Kristen R. Ehresmann, RN, MPH, Minnesota Department of Health, St. Paul, Minnesota; Janet Englund, MD, Children's Hospital and Regional Medical Center, Seattle, Washington; Carol Friedman, DO (Lead Staff, ACIP Adult Immunization Working Group), Centers for Disease Control and Prevention, Atlanta, Georgia; Franklyn N. Judson, MD, University of Colorado Health Science Center, Denver, Colorado; Wendy A. Keitel, MD, Baylor College of Medicine, Houston, Texas; Susan M. Lett, MD, MPH, Massachusetts Department of Public Health, Jamaica Plain, Massachusetts; Michael S. Marcy, MD, Harbor-UCLA Medical Center, Torrance, California; Cody H. Meissner, MD, Tufts Medical Center, Boston, Massachusetts; Georgia; Kathleen Neuzil, MD, MPH, University of Washington, Seattle, Washington; Mark H. Sawyer, MD, UCSD School of Medicine and Rady Children's Hospital San Diego, San Diego, California; Ciro Valent Sumaya, MD, MPHTM, Texas A&M Health Science Center, College Station, Texas; and Jonathan Temte, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From the Centers for Disease Control and Prevention, Atlanta, Georgia.Disclosures: To assure the integrity of the ACIP, the U.S. Department of Health and Human Services has taken steps to assure that there is technical compliance with ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed, or avoided altogether, through both pre-and postappointment considerations. Individuals with particular vaccine-related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest, and if any are found, they are asked to divest or forgo certain vaccine-related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare his or her conflicts. Members with conflicts are not permitted to vote if the conflict involves the vaccine or biologic being voted upon. Members of the ACIP have disclosed the following: Grants received: J. Englund (MedImmune, Sanofi Pasteur, Novartis); W.A. Keitel (Novartis). Payments made to Tufts Medical Center for participation in clinical trials: C.H. Meissner (MedImmune, Wyeth).Corresponding Author: Carol Friedman, DO, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Mailstop E52, Atlanta, GA 30333; e-mail, cxf7@cdc.gov.* The 2010 ACIP Adult Immunization Schedule appeared simultaneously in Annals of Internal Medicine and MMWR Recommendations and Reports. Readers who wish to cite the schedule should use the following citation: Advisory Committee on Immunization Practices. Recommended Adult Immunization Schedule: United States, 2010. Ann Intern Med. 2010:152:36-9.† For a list of the Advisory Committee on Immunization Practices, see the Appendix. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAdult Immunization Guidelines: Challenges and Opportunities Robert H. Hopkins Jr. and Keyur S. Vyas Metrics Cited byNeurologic Complications of Corticosteroids in Cancer TherapyIncidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel DiseaseCaring for Older Adults with the Human Immunodeficiency VirusHPV vaccine acceptance among a sample of Southern men who have sex with men: A comparison of younger and older menLGBT health and vaccinations: Findings from a community health survey of Lexington-Fayette County, Kentucky, USACorynebacteriaEnfermedad de Crohn. Enfoque diagnóstico y terapéutico de las primeras visitasApproach and Management of Patients with Chronic Hepatitis B and C During the Course of Inflammatory Bowel DiseaseVaccination in HIV positive adults: Need to addressBurden of vaccine-preventable disease in adult Medicaid and commercially insured populationsGuidelines for prevention of hospital acquired infectionsHealth Care Providers' Perspectives on Low HPV Vaccine Uptake and Adherence in Appalachian KentuckyScreening for Cervical Cancer in Low-Resource Settings in 2011Vaccination strategies in patients with IBDMicrobial Vaccine DevelopmentDPneumococcal polysaccharide vaccinesRandomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy AdultsComparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel diseaseVulvar CancerPrevention of Hepatitis Infection in HIV-Infected PatientsHuman Papillomavirus Vaccine Intention Among College Men: What's Oral Sex Got to Do With It?Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-infected KoreansHPV-Related Risk Perceptions and HPV Vaccine Uptake Among a Sample of Young Rural WomenQ & A: Patient to Physician FAQs: Answers to Common Patient Questions About VaccinationsSexually Related Behaviors as Predictors of HPV Vaccination Among Young Rural WomenThe Relationship Between Intervening Hospitalizations and Transitions Between Frailty StatesPublic Health Implications of Rapid Hepatitis C Screening With an Oral Swab for Community-Based Organizations Serving High-Risk PopulationsComplex Decisions in Managing HIV Infection During PregnancyResearch Priorities for High-quality Geriatric Emergency Care: Medication Management, Screening, and Prevention and Functional AssessmentIs male intent to be vaccinated against HPV a function of the promotion message?Gardasil for guys: correlates of intent to be vaccinatedCirculating Human Antibody-Secreting Cells during Vaccinations and Respiratory Viral Infections Are Characterized by High Specificity and Lack of Bystander EffectPrevention of infections in patients with autoimmune diseasesBuilding a Departmental Quality Program: A Patient-Based and Provider-Led ApproachReview article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel diseaseA 24-Year-Old Patient With Crohn's Disease Starting Immunosuppressive Therapy: Vaccination Issues to ConsiderKeeping our Adult Patients Healthy and Active: The Role of Vaccines across the LifespanInfectious Diseases in End-Stage Liver Disease PatientsViral Infections in Pregnancy other than Human Immunodeficiency VirusUpdated adult immunization guidelinesVaccination against tetanus, diphtheria, pertussis and poliomyelitis in adult travellersAdult Immunization Guidelines: Challenges and OpportunitiesRobert H. Hopkins Jr., MD and Keyur S. Vyas, MDRecent Update in Adult Immunization 5 January 2010Volume 152, Issue 1Page: 36-39KeywordsChild healthConflicts of interestHaemophilus influenzae type BHepatitis AHepatitis BHospital medicineHuman papillomavirusMMR vaccinePrevention, policy, and public healthVaccines ePublished: 5 January 2010 Issue Published: 5 January 2010 PDF downloadLoading ...
Loading…
Stored only when both papers are in the corpus — 52 citations exist upstream.
Imported from OpenAlex (CC0) — nothing here is generated.